Targeting with oligomannose-coated liposomes promotes maturation and splenic trafficking of dendritic cells in the peritoneal cavity

Ishii, Mariko; Kato, Chikaki; Hakamata, Ayumi; Kojima, Naoya

doi:10.1016/j.intimp.2010.11.011

Cited by 20 publications

(13 citation statements)

References 43 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon OML uptake, expression of CD80, CD86, CD40 and MHC class II molecules on OMLcontaining peritoneal macrophages was significantly enhanced (18). We also demonstrated that the expression levels of CCR7 and CD205, both of which are markers of cell maturity in murine DCs, were clearly upregulated on resident peritoneal DCs with ingested OMLs (32). Expression of CCR7 is essential for trafficking of APCs to secondary lymphoid organs to present antigens to naïve T cells, and therefore enhancement of CCR7 by OML uptake may promote migration of APCs from peripheral tissues to secondary lymphoid tissues.…”

Section: Omls Promote Activation Maturation and Trafficking Of Apcssupporting

confidence: 51%

“…Expression of CCR7 is essential for trafficking of APCs to secondary lymphoid organs to present antigens to naïve T cells, and therefore enhancement of CCR7 by OML uptake may promote migration of APCs from peripheral tissues to secondary lymphoid tissues. Indeed, we found that DCs traveled into the spleen from the peritoneal cavity within 24 h after OML uptake (32). Recently, we have shown that in vivo uptake of OMLs by peritoneal cells of a monocyte/macrophage lineage promotes differentiation of the cells along a DC lineage without exogenous cytokines (33).…”

Section: Omls Promote Activation Maturation and Trafficking Of Apcsmentioning

confidence: 87%

“…Preferential production of IL-12 from peritoneal cells that ingested OMLs provided further evidence for activation of APCs by OMLs (18,32). IL-12 is a heterodimeric cytokine secreted by APCs and is critical for development of Th1 cells and initiation of a cell-mediated immune response (35).…”

Section: Omls Promote Activation Maturation and Trafficking Of Apcsmentioning

confidence: 99%

“…IL-12 is a heterodimeric cytokine secreted by APCs and is critical for development of Th1 cells and initiation of a cell-mediated immune response (35). DCs, rather than macrophages, are the main producers of IL-12 in response to OML uptake among the OMLcontaining peritoneal cells (32), suggesting that production and secretion of IL-12 from OML-containing DCs may be a crucial event in induction of OML-stimulated Th1 immune responses. Interestingly, production of inflammatory cytokines such as IL-1 and IL-6 from both DCs and macrophages was suppressed in response to OML incorporation, while production of IL-12 from peritoneal cells was clearly promoted in DCs (18).…”

Section: Omls Promote Activation Maturation and Trafficking Of Apcsmentioning

confidence: 99%

See 3 more Smart Citations

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Kojima

Kawauchi

Ishii

2011

TIGG

Self Cite

View full text Add to dashboard Cite

Antigen delivery systems are important for inducing and modifying immune responses. A key to development of vaccines is the ability to deliver antigens to antigenpresenting cells (APCs) more efficiently and to induce subsequent activation of T cell-mediated immunity. Thus, strategies that target APCs and modulate APC functions in vivo have significant implications for vaccine design. We have demonstrated that oligomannose-coated liposomes (OMLs), which consist of DPPC, cholesterol, Man3-DPPE at a molar ratio of 10:10:1, can induce strong cellular immunity. In this review, we discuss OMLs as novel antigen-delivery vehicles that also have a strong adjuvant effect on induction of Th1 immune responses and CTLs specific for the encased antigen. This property of OMLs is due to their ability to assist specific cellular uptake in vivo and to promote subsequent APC maturation, presentation of antigens on APCs, preferential secretion of IL-12 from APCs, and migration of APCs into lymphoid tissues from peripheral tissues. Administration of an OML-based vaccine can eliminate an established tumor, inhibit elevation of the serum level of IgE against an allergen, and prevent progression of some protozoan infections in mouse models. In addition, OMLs with an encased antigen are able to induce antigen-specific CTLs in PBMCs obtained from patients. These feasibility studies of OML-based vaccines have revealed their potential for clinical use in vaccination for diseases in which CTLs and/or Th1 cells act as effector cells.

show abstract

Section: Omls Promote Activation Maturation and Trafficking Of Apcssupporting

confidence: 51%

Section: Omls Promote Activation Maturation and Trafficking Of Apcsmentioning

confidence: 87%

Section: Omls Promote Activation Maturation and Trafficking Of Apcsmentioning

confidence: 99%

Section: Omls Promote Activation Maturation and Trafficking Of Apcsmentioning

confidence: 99%

See 2 more Smart Citations

Development of Novel Carbohydrate-Coated Liposome-Based Vaccines

Kojima

Kawauchi

Ishii

2011

TIGG

Self Cite

View full text Add to dashboard Cite

show abstract

“…The pre-treatment of unsensitized mice with Cry j 1/ OMLs blocked total and allergen-specific IgE levels in sera from Cry j 1 sensitized animals, with decreased IgG1 as well and significantly increased levels of specific IgG2a. [66][67][68] Liposome-protamine-DNA (LPD) NPs are safe, effective, and non-toxic adjuvants that induce Th1-like immune responses. Nouri et al demonstrated that the encapsulation of rChe a 1, rChe a 2, and rChe a 3 allergens (produced in a recombinant hybrid form [rHM]) from Chenopodium album resulted in a reduction in specific IgE and a marked increase in IgG2a in a murine model.…”

mentioning

confidence: 99%

Nanoparticle–allergen complexes for allergen immunotherapy

Felice¹,

Colombo²

2017

IJN

View full text Add to dashboard Cite

Allergen-specific immunotherapy was introduced in clinical settings more than 100 years ago. It remains the only curative approach to treating allergic disorders that ameliorates symptoms, reduces medication costs, and blocks the onset of new sensitizations. Despite this clinical evidence and knowledge of some immunological mechanisms, there remain some open questions regarding the safety and efficacy of this treatment. This suggests the need for novel therapeutic approaches that attempt to reduce the dose and frequency of treatment administration, improving patient compliance, and reducing costs. In this context, the use of novel adjuvants has been proposed and, in recent years, biomedical applications using nanoparticles have been exploited in the attempt to find formulations with improved stability, bioavailability, favorable biodistribution profiles, and the capability of targeting specific cell populations. In this article, we review some of the most relevant regulatory aspects and challenges concerning nanoparticle-based formulations with immunomodulatory potential, their related immunosafety issues, and the nature of the nanoparticles most widely employed in the allergy field. Furthermore, we report in vitro and in vivo data published using allergen/nanoparticle systems, discuss their impact on the immune system in terms of immunomodulatory activity and the reduction of side effects, and show that this strategy is a novel and promising tool for the development of allergy vaccines.

show abstract